Document:

<PAGE>
                                                                    Exhibit 10.2

                                                            BLAKE DAWSON WALDRON
                                                                   LAWYERS

                              AMENDED AND RE-STATED
                            MANUFACTURING LICENCE AND
                                SUPPLY AGREEMENT

                                 GLYCOTEX, INC.

                        NOVOGEN LABORATORIES PTY LIMITED
                               ABN 42 002 489 947

            Level 35, Grosvenor Place
                    225 George Street
                      SYDNEY NSW 2000
                 Telephone: 9258 6000
                       Fax: 9258 6999   REF: BLM SJH 02 1389 1453

                          (C) BLAKE DAWSON WALDRON 2005
<PAGE>
                                    CONTENTS

<TABLE>
<S>  <C>                                                                      <C>
1.   INTERPRETATION                                                            1

     1.1  DEFINITIONS                                                          1
     1.2  RULES FOR INTERPRETING THIS DOCUMENT                                 5
     1.3  BUSINESS DAYS                                                        6

2.   MANUFACTURING LICENCE                                                     6

     2.1  GRANT OF LICENCE                                                     6
     2.2  SUB-LICENCES                                                         7
     2.3  EXPIRATION OF PATENT RIGHTS                                          7
     2.4  SUB-CONTRACTORS                                                      7

3.   SUPPLY OF COMPOUND                                                        7

     3.1  SUPPLY OF COMPOUND                                                   7
     3.2  FORECASTS OF SUPPLY REQUIREMENTS                                     7
     3.3  NOTICE REQUIREMENTS ON REGULATORY FILINGS                            7
     3.4  PURCHASE ORDERS                                                      8
     3.5  CONFIRMATION OF PURCHASE ORDERS                                      8
     3.6  FULFILMENT OF PURCHASE ORDERS                                        8
     3.7  PLACE OF DELIVERY                                                    8
     3.8  PACKING AND TRANSPORT OF COMPOUND                                    8
     3.9  FAILURE TO SUPPLY                                                    9
     3.10 ALTERNATIVE SUPPLY ARRANGEMENTS                                      9

4.   TITLE AND RISK                                                           10

     4.1  PASSING OF TITLE TO COMPOUND                                        10
     4.2  RISK                                                                10

5.   FEES FOR THE SUPPLY OF COMPOUND                                          10

     5.1  PURCHASE PRICE                                                      10
     5.2  INVOICES FOR PURCHASE PRICE                                         10
     5.3  TIME FOR PAYMENT                                                    10
     5.4  REVIEWS OF THE PURCHASE PRICE                                       10
     5.5  ADJUSTMENT OF PURCHASE PRICE                                        10
     5.6  SUSPENSION OF SUPPLY                                                11
     5.7  INSPECTION                                                          11

6.   PAYMENT TERMS                                                            11

     6.1  PAYMENTS                                                            11
     6.2  INTEREST ON OVERDUE ACCOUNTS                                        11
     6.3  TERMINATION                                                         11
</TABLE>
<PAGE>
<TABLE>
<S>  <C>                                                                      <C>
7.   GOODS AND SERVICES TAX                                                   11

     7.1  GST LAW DEFINITIONS                                                 11
     7.2  GST PAYABLE IN ADDITION TO OTHER AMOUNTS                            11
     7.3  TAX INVOICE                                                         12
     7.4  ADJUSTMENTS                                                         12
     7.5  GST WHERE GLYCOTEX SUPPLIES NOVOGEN LABORATORIES                    12

8.   MANUFACTURING DEVELOPMENTS AND IMPROVEMENTS                              13

     8.1  MANUFACTURING DEVELOPMENTS                                          13
     8.2  MANUFACTURING IMPROVEMENTS                                          13
     8.3  TECHNICAL ASSISTANCE                                                13

9.   INTELLECTUAL PROPERTY RIGHTS                                             13

     9.1  ACKNOWLEDGMENT                                                      13
     9.2  NOTIFICATION                                                        13
     9.3  JOINDER OF NOVOGEN LABORATORIES                                     13

10.  CONFIDENTIAL INFORMATION                                                 14

     10.1 CONFIDENTIALITY                                                     14
     10.2 SECURITY                                                            14
     10.3 EXCEPTIONS TO OBLIGATIONS OF CONFIDENTIALITY                        14
     10.4 PUBLIC DOMAIN                                                       14

11.  REPRESENTATIONS AND WARRANTIES                                           14

     11.1 WARRANTIES OF EACH PARTY                                            14
     11.2 REPRESENTATIONS AND WARRANTIES BY NOVOGEN LABORATORIES              15
     11.3 RELIANCE ON REPRESENTATIONS AND WARRANTIES                          15
     11.4 EXCLUSION OF CONDITIONS AND WARRANTIES                              15

12.  LIMITATION OF LIABILITY                                                  16

     12.1 INDIRECT AND CONSEQUENTIAL LOSS                                     16
     12.2 STATUTORY WARRANTIES                                                16
     12.3 BARRING OF CLAIMS FOR QUANTITY SHORTFALLS OR DAMAGE                 16
     12.4 BARRING OF CLAIMS FOR DEFECTS IN QUALITY                            17

13.  INDEMNITIES AND INSURANCE                                                17

     13.1 CLINICAL TRIAL INDEMNITY                                            17
     13.2 COMMERCIALISATION INDEMNITY                                         17
     13.3 GLYCOTEX'S INSURANCE POLICIES                                       17
     13.4 NAME OF NOVOGEN LABORATORIES                                        18
     13.5 CERTIFICATES OF CURRENCY                                            18
     13.6 DEFAULT                                                             18
     13.7 EXPIRY                                                              18
     13.8 NOVOGEN LABORATORIES' INSURANCE                                     18
</TABLE>

                                                                             ii.
<PAGE>
<TABLE>
<S>  <C>                                                                      <C>
14.  FORCE MAJEURE                                                            18

     14.1 NOTICE AND SUSPENSION OF OBLIGATIONS                                18
     14.2 EFFORT TO OVERCOME                                                  19
     14.3 TERMINATION                                                         19

15.  TERM AND TERMINATION                                                     19

     15.1 TERM                                                                19
     15.2 TERMINATION BY GLYCOTEX                                             19
     15.3 TERMINATION BY NOVOGEN LABORATORIES                                 20
     15.4 CONSEQUENCES OF TERMINATION                                         20
     15.5 SURVIVAL AND ACCRUED RIGHTS                                         20

16.  DISPUTE RESOLUTION                                                       20

     16.1 DISPUTES                                                            20
     16.2 NOTICE OF DISPUTE                                                   21
     16.3 NEGOTIATION                                                         21
     16.4 RESOLUTION OF DISPUTE                                               21
     16.5 MEDIATION                                                           21

17.  NOTICES                                                                  21

18.  AMENDMENT AND ASSIGNMENT                                                 22

     18.1 AMENDMENT                                                           22
     18.2 ASSIGNMENT                                                          22

19.  GENERAL                                                                  22

     19.1 GOVERNING LAW                                                       22
     19.2 LIABILITY FOR EXPENSES                                              22
     19.3 RELATIONSHIP OF THE PARTIES                                         22
     19.4 GIVING EFFECT TO THIS DOCUMENT                                      22
     19.5 WAIVER OF RIGHTS                                                    23
     19.6 OPERATION OF THIS DOCUMENT                                          23
     19.7 EXCLUSION OF CONTRARY LEGISLATION                                   23
     19.8 COUNTERPARTS                                                        23

SCHEDULE: GLUCAN PATENT RIGHTS                                                25
</TABLE>

                                                                            iii.
<PAGE>
        AMENDED AND RE-STATED MANUFACTURING LICENCE AND SUPPLY AGREEMENT

DATE September 2005

PARTIES

     GLYCOTEX, INC., a company incorporated under the laws of Delaware, United
     States of America, c/- 1 Landmark Square, Suite 240, Stamford Connecticut
     06901, USA (GLYCOTEX)

     NOVOGEN LABORATORIES PTY LTD ABN 42 002 489 947 (NOVOGEN LABORATORIES)

RECITALS

A.   Novogen Research has granted to Glycotex a worldwide exclusive licence to
     exploit the Licensed Intellectual Property for certain human therapeutic
     uses on the terms and conditions of the Licence Agreement.

B.   Novogen Laboratories has expertise and experience in the manufacture of
     oligosaccharides including the Compound.

C.   Glycotex granted to Novogen Laboratories a sub-licence to manufacture the
     Compound and to supply the Compound to Glycotex on the terms and conditions
     of the Manufacturing Licence and Supply Agreement dated 30 April 2003.

D.   The parties now amend and re-state the Manufacturing Licence and Supply
     Agreement in accordance with this document.

OPERATIVE PROVISIONS

1.   INTERPRETATION

1.1  DEFINITIONS

     The following definitions apply in this document.

     BUSINESS DAY means a day that is not a Saturday, Sunday or public holiday
     in Sydney, Australia.

     CHANGE IN CONTROL, in relation to Glycotex means:

     (a)  the acquisition by any Person or Group other than Novogen Limited of
          more than 50% of the combined voting power of the then outstanding
          securities entitled to vote generally in the election of directors of
          Glycotex; or

     (b)  any merger, consolidation, reorganization, recapitalization, tender or
          exchange offer or any other transaction with or effecting Glycotex as
          a result of which a Person or Group other than the stockholders of
          Glycotex immediately before the transaction owns after the transaction
          more than 50% of the combined voting power of the then outstanding
          securities entitled to vote generally in the election of the directors
          of Glycotex,
<PAGE>
     but does not include any acquisition as a result of, or transaction
     involving, an initial public offering of Glycotex's common stock.

     CLINICAL TRIAL means a clinical evaluation of the stability, tolerability,
     synergy or efficacy of a Product.

     COMMENCEMENT DATE means the date this document is executed by the last of
     the parties to execute it.

     COMPOUND means the compound known as (beta)-(1,3)(1,6) glucan in its
     primary manufactured form.

     CONFIDENTIAL INFORMATION means all Glucan Know How and all written or oral
     information disclosed by Glycotex to Novogen Laboratories under this
     document, other than information which Novogen Laboratories can establish:

     (a)  was in the public domain when it was given to Novogen Laboratories;

     (b)  becomes, after being given to Novogen Laboratories, part of the public
          domain, except through disclosure contrary to this document; or

     (c)  was lawfully received by Novogen Laboratories from another person
          having the unrestricted legal right to disclose that information
          without requiring the maintenance of confidentiality.

     CONTROL means a power or control that is direct or indirect or that is, or
     can be, exercised as a result of, by means of or by the revocation or
     breach of a trust, an agreement, a practice, or any combination of them,
     whether or not they are enforceable. It does not matter whether the power
     or control is express or implied, formal or informal, exercisable alone or
     jointly with someone else.

     CORPORATIONS ACT means the Corporations Act 2001 (Cth).

     DEFAULT RATE means, in relation to an amount which has not been paid to a
     party, a rate equal to the sum of that party's cost of funding the amount
     (if that party were to borrow that amount and as determined conclusively by
     that party) and 2% per annum.

     DISPUTE has the meaning given to that term in clause 16.1.

     DISPUTE NOTICE has the meaning given to that term in clause 16.2.

     ENCUMBRANCE means a mortgage, charge, pledge, lien, hypothecation or title
     retention arrangement, a right of set-off or right to withhold payment of a
     deposit or other money, a notice under section 255 of the Income Tax
     Assessment Act 1936 (Cth), section 260-5 in schedule 1 to the Taxation
     Administration Act 1953 (Cth) or any similar legislation, or an easement,
     restrictive covenant, caveat or similar restriction over property, or an
     agreement to create any of them or to allow any of them to exist.

                                                                              2.
<PAGE>
     FIELD means the fields of:

     (a)  therapeutic treatment of skin ulceration (including pressure sores,
          bed sores, venous ulcers, diabetic ulcers and burns) in humans;

     (b)  treatment of bone fracture and the enhancement of fixation of
          implanted orthopaedic devices (including pins, screws and artificial
          joints) in humans;

     (c)  prevention/treatment of ultraviolet light induced skin damage in
          humans;

     (d)  treatment of injured connective tissues (including injuries to tendons
          and ligaments, such as sporting injuries, inflammation and surgical
          injury) in humans;

     (e)  joint repair (particularly with artificial joints) in humans; and

     (f)  treatment of poorly healing surgically dissected or transected tissue
          in humans.

     GLUCAN KNOW HOW has the meaning given to that term in the Licence
     Agreement.

     GLUCAN PATENT RIGHTS means all Patent Rights in the patents and patent
     applications set out in schedule 1.

     GOVERNMENT AGENCY means:

     (a)  a government or government department or other body;

     (b)  a governmental, semi-governmental or judicial person; or

     (c)  a person (whether autonomous or not) who is charged with the
          administration of a law.

     GROUP means two or more Persons acting as a partnership, limited
     partnership, syndicate, or other group for the purpose of acquiring,
     holding, or disposing of any securities.

     GST means:

     (a)  the same as in the GST Law; and

     (b)  any other goods and services tax, or any tax applying to this
          transaction in a similar way; and

     (c)  any additional tax, penalty tax, fine, interest or other charge under
          a law for such a tax.

     GST LAW means the same as "GST law" means in A New Tax System (Goods and
     Services Tax) Act 1999 (Cth).

     INCOTERMS means the international rules for the interpretation of trade
     terms in foreign trade known as "Incoterms" published by the International
     Chamber of Commerce.

     INSOLVENCY EVENT means, for a person, being in liquidation or provisional
     liquidation or under administration, having a controller or analogous
     person appointed to it or any of its

                                                                              3.
<PAGE>
     property, being taken to have failed to comply with a statutory demand,
     being unable to pay its debts or otherwise insolvent, dying, ceasing to be
     of full legal capacity or otherwise becoming incapable of managing its own
     affairs for any reason, taking any step that could result in the person
     becoming an insolvent under administration, entering into a compromise or
     arrangement with, or assignment for the benefit of, any of its members or
     creditors, or any analogous event.

     INTELLECTUAL PROPERTY RIGHTS means any and all existing and future
     intellectual and industrial property rights throughout the world, whether
     conferred by statute, common law or equity, including rights in relation to
     copyright, trade marks, designs, circuit layouts, plant varieties, business
     and domain names, trade secrets and Know How (including the right to apply
     for registration of any such rights), Patent Rights and other results of
     intellectual activity in the industrial, commercial, scientific, literary
     or artistic fields.

     KNOW HOW means technical and other information which is not in the public
     domain including inventions, discoveries, concepts, data, formulae, ideas,
     specifications, procedures for experiments and tests, results of
     experimentation and testing, results of research and development and
     information in laboratory records, data collected during the course of
     clinical trials, case reports, data analyses and summaries and submissions
     to and information from ethics committees and regulatory authorities.

     LICENCE AGREEMENT means the agreement entitled "Amended and Re-stated
     Technology Licence Agreement" between Novogen Research and Glycotex dated
     on or about the date of this document.

     LICENSED INTELLECTUAL PROPERTY means the rights granted to Glycotex under
     the Licence Agreement, which include rights under the Glucan Patent Rights
     and Intellectual Property Rights in the Glucan Know How.

     MANUFACTURING DEVELOPMENTS means all developments, improvements,
     enhancements, adaptations and new Know How, whether patentable or
     otherwise, in relation to the synthesis and manufacture of the Compound
     which during the Term are made or acquired by Glycotex, its employees or
     agents, which Glycotex is free to license or disclose.

     MANUFACTURING IMPROVEMENTS means all improvements, developments,
     enhancements, adaptations and new Know How, whether patentable or
     otherwise, in relation to the synthesis and manufacture of the Compound,
     which during the Term are made or acquired by Novogen Laboratories, its
     employees, agents or contractors.

     NOVOGEN RESEARCH means Novogen Research Pty Limited.

     PATENT RIGHTS means existing and future patents (including any divisions,
     continuations, continuations in part, renewals, reissues, extensions,
     supplementary protection certificates, utility models and foreign
     equivalents thereof) and rights with respect to existing and future patent
     applications and patentable inventions, including the right to apply for
     registration of any such rights.

     PERSON means a natural person, company, government, or political
     subdivision, agency, or instrumentality of a government.

                                                                              4.
<PAGE>
     PRODUCT means any product or formulation containing (beta)-(1,3)(1,6)
     glucan for use in the Field, whether in primary manufactured form, final
     packaged form or otherwise, and whether in combination with any other
     compound or component, active or otherwise.

     PURCHASE ORDER has the meaning given to that term in clause 3.4.

     PURCHASE PRICE in respect of a quantity of Compound means the total of:

     (a)  the cost to Novogen Laboratories of the raw materials used or
          incorporated into the Compound;

     (b)  all labour and on costs of Novogen Laboratories in the manufacture and
          delivery of the Compound;

     (c)  all manufacturing and general overheads of Novogen Laboratories in the
          manufacture and delivery of the Compound;

     (d)  all equipment and facilities costs (including any financing costs) of
          Novogen Laboratories in the manufacture and delivery of the Compound;
          and

     (e)  any other costs incidental to the costs in paragraphs (a) to (d), or
          otherwise incidental to the manufacture, supply or delivery of the
          Compound under this document,

     plus a mark-up amount of 50% of that total.

     QUARTER means, in respect of any calendar year in the Term, each of the
     four quarters of that year, the first of which commences on the first day
     of that year.

     SUPPLY DATE means a date for supply of Compound specified in a Purchase
     Order.

     TERM means the term of this document as determined under clause 15.

     TERRITORY means the world.

1.2  RULES FOR INTERPRETING THIS DOCUMENT

     Headings are for convenience only, and do not affect interpretation. The
     following rules also apply in interpreting this document, except where the
     context makes it clear that a rule is not intended to apply.

     (a)  A reference to:

          (i)  legislation (including subordinate legislation) is to that
               legislation as amended, re-enacted or replaced, and includes any
               subordinate legislation issued under it;

          (ii) a document or agreement, or a provision of a document or
               agreement, is to that document, agreement or provision as
               amended, supplemented, replaced or novated;

                                                                              5.
<PAGE>
          (iii) a party to this document or to any other document or agreement
               includes a permitted substitute or a permitted assign of that
               party;

          (iv) a person includes any type of entity or body of persons, whether
               or not it is incorporated or has a separate legal identity, and
               any executor, administrator or successor in law of the person;
               and

          (v)  anything (including a right, obligation or concept) includes each
               part of it.

     (b)  A singular word includes the plural, and vice versa.

     (c)  A word which suggests one gender includes the other genders.

     (d)  If a word is defined, another part of speech has a corresponding
          meaning.

     (e)  If an example is given of anything (including a right, obligation or
          concept), such as by saying it includes something else, the example
          does not limit the scope of that thing.

     (f)  The word AGREEMENT includes an undertaking or other binding
          arrangement or understanding, whether or not in writing.

     (g)  The words SUBSIDIARY, HOLDING COMPANY and RELATED BODY CORPORATE have
          the same meanings as in the Corporations Act.

1.3  BUSINESS DAYS

     If the day on or by which a person must do something under this document is
     not a Business Day:

     (a)  if the act involves a payment that is due on demand, the person must
          do it on or by the next Business Day; and

     (b)  in any other case, the person must do it on or by the previous
          Business Day.

2.   MANUFACTURING LICENCE

2.1  GRANT OF LICENCE

     Glycotex by this document grants to Novogen Laboratories for the Term a
     non-transferable, exclusive sub-licence under the Licensed Intellectual
     Property and any Intellectual Property Rights in Manufacturing Developments
     and Manufacturing Improvements, to:

     (a)  make and keep the Compound in the Territory;

     (b)  supply the Compound to Glycotex anywhere in the Territory on the terms
          and conditions of this document; and

     (c)  keep, use, reproduce, apply, develop, modify and enhance the Glucan
          Know How, Manufacturing Improvements and Manufacturing Developments in
          the Territory for the purposes of exercising its rights under
          paragraphs (a) and (b).

                                                                              6.
<PAGE>
2.2  SUB-LICENCES

     Novogen Laboratories must not grant any sub-licence of any of the rights
     granted to it under clause 2.1 without the prior written consent of
     Glycotex.

2.3  EXPIRATION OF PATENT RIGHTS

     If during the Term all Patent Rights in the Licensed Intellectual Property
     in any country in the Territory lapse, are abandoned or are held invalid,
     then subject to clause 15.1, the licence granted in clause 2.1 shall
     continue in full force and effect in that country on the same terms as a
     licence under the Intellectual Property Rights in the Glucan Know How, the
     Manufacturing Improvements and Manufacturing Developments only.

2.4  SUB-CONTRACTORS

     Novogen Laboratories must not engage agents or sub-contractors to exercise
     its rights or to perform its obligations under this document without the
     prior written consent of Glycotex.

3.   SUPPLY OF COMPOUND

3.1  SUPPLY OF COMPOUND

     Novogen Laboratories agrees to supply Compound to Glycotex on the terms and
     conditions of this document.

3.2  FORECASTS OF SUPPLY REQUIREMENTS

     Within 20 Business Days following the Commencement Date, and thereafter at
     least 30 days prior to the end of each Quarter, Glycotex shall provide to
     Novogen Laboratories a rolling forecast which specifies Glycotex's
     estimated requirements for supply of Compound for the following four
     Quarters, which includes:

     (a)  the volume of Compound estimated to be required for the purposes of
          Clinical Trials;

     (b)  the volume of Compound estimated to be required for the purposes of
          commercialisation; and

     (c)  the anticipated Supply Dates.

3.3  NOTICE REQUIREMENTS ON REGULATORY FILINGS

     Glycotex acknowledges that in order for Novogen Laboratories to manufacture
     and accumulate sufficient stock of Compound prior to any commercial launch
     of a Product, Novogen Laboratories must have adequate notice of the date of
     commercial launch. Accordingly, Glycotex must:

     (a)  notify Novogen Laboratories in writing promptly upon filing any
          application to the US Food and Drug Administration or equivalent
          Government Agency in another country for marketing approval of any
          Product (a MARKETING APPLICATION); and

                                                                              7.
<PAGE>
     (b)  keep Novogen Laboratories reasonably informed from time to time of the
          progress of all Marketing Applications.

3.4  PURCHASE ORDERS

     Subject to clause 3.3, at least 8 weeks prior to any proposed Supply Date,
     Glycotex must provide to Novogen Laboratories a written order for Compound,
     having regard to the forecasts provided by Glycotex under clause 3.2 (a
     PURCHASE ORDER). Each Purchase Order must include:

     (a)  the volume of Compound required;

     (b)  the indicative Supply Date; and

     (c)  the place at which delivery is to be made under clause 3.7.

3.5  CONFIRMATION OF PURCHASE ORDERS

     Within 5 Business Days of receiving a Purchase Order, Novogen Laboratories
     shall notify Glycotex in writing:

     (a)  that it has received that Purchase Order; and

     (b)  the volume of Compound in the Purchase Order which Novogen
          Laboratories is able to supply by the Supply Date.

3.6  FULFILMENT OF PURCHASE ORDERS

     Upon confirmation of a Purchase Order under clause 3.5, Novogen
     Laboratories shall:

     (a)  ensure that it manufactures, and has available for delivery by the
          Supply Date, the volume of Compound notified under clause 3.5(b);

     (b)  deliver to Glycotex by the Supply Date the volume of Compound notified
          under clause 3.5(b); and

     (c)  otherwise use all reasonable endeavours to manufacture and have
          available for delivery sufficient quantities of Compound to supply to
          Glycotex, by the Supply Date, the quantity of Compound specified in
          the Purchase Order.

3.7  PLACE OF DELIVERY

     Novogen Laboratories shall deliver all Compound C.I.F. (Incoterms, 2000) to
     Glycotex at a port within the Territory nominated by Glycotex. Unless the
     parties agree otherwise in writing, Glycotex may nominate only one port for
     delivery in fulfilment of each Purchase Order.

3.8  PACKING AND TRANSPORT OF COMPOUND

     Novogen Laboratories must ensure that all Compound to be supplied to
     Glycotex under this clause 3 is packed in a secure and appropriate manner
     so that it is reasonably likely to reach Glycotex in good condition under
     normal conditions of transport.

                                                                              8.
<PAGE>
3.9  FAILURE TO SUPPLY

     If Novogen Laboratories materially and persistently fails to supply to
     Glycotex, by the Supply Dates, the volume of Compound requested in Purchase
     Orders provided by Glycotex under clause 3.4 (other than as a result of a
     suspension under clause 5.6 or clause 14.1) then:

     (a)  Glycotex may itself manufacture, or may enter into an agreement with a
          third party, pursuant to which that third party is licensed to
          manufacture and supply to Glycotex, the quantity of Compound required
          by Glycotex which exceeds the quantity which Novogen Laboratories is
          able to supply to Glycotex under this document; and

     (b)  Novogen Laboratories must take all reasonable steps to make available
          to Glycotex or the third party (as the case may be) on reasonable
          commercial terms such Know How of Novogen Laboratories as is necessary
          to enable Glycotex or the third party (as the case may be) to
          manufacture the additional quantity of Compound referred to in
          paragraph (a),

     until such time as Novogen Laboratories demonstrates that it is
     consistently able to supply the quantity of Compound which meets Glycotex's
     requirements.

3.10 ALTERNATIVE SUPPLY ARRANGEMENTS

     (a)  Despite the licence granted to Novogen Laboratories in clause 2.1:

          (i)  at any time during the Term Glycotex may give a third party such
               information and assistance as is necessary for the third party to
               develop a capability to manufacture and supply to Glycotex the
               quantity of Compound required by Glycotex which exceeds the
               quantity which Novogen Laboratories is able to supply to Glycotex
               under this document; and

          (ii) if either party has given a notice of termination under clause
               15, Glycotex may give a third party such assistance as is
               necessary for the third party to develop a capability to
               manufacture and supply to Glycotex its requirements for Compound
               after termination of this document.

     (b)  For the purpose of paragraph (a), Glycotex may disclose to the
          relevant third party any Glucan Know How, Manufacturing Improvements
          and Manufacturing Developments as are necessary to develop the
          relevant capability.

     (c)  Within 5 Business Days of exercising its rights under paragraphs (a)
          or (b), Glycotex must give Novogen Laboratories notice in writing of
          the identity of the third party together with details of the
          information or assistance provided, and the Glucan Know How,
          Manufacturing Improvements or Manufacturing Developments disclosed.

                                                                              9.
<PAGE>
4.   TITLE AND RISK

4.1  PASSING OF TITLE TO COMPOUND

     Novogen Laboratories retains property in and ownership of all Compound
     supplied to Glycotex until the Compound has been delivered to Glycotex or
     its carrier, at which time property and ownership passes to Glycotex.

4.2  RISK

     All Compound is at Glycotex's risk from the first to occur of:

     (a)  the physical delivery of the Compound to Glycotex; or

     (b)  the physical delivery of the Compound to a carrier for delivery to
          Glycotex (even if the carrier has not been nominated or retained by
          Glycotex).

5.   FEES FOR THE SUPPLY OF COMPOUND

5.1  PURCHASE PRICE

     In consideration of the supply of Compound to Glycotex under clause 3,
     Glycotex must pay to Novogen Laboratories the Purchase Price on the terms
     and conditions of this document.

5.2  INVOICES FOR PURCHASE PRICE

     Within 5 Business Days of delivery of Compound to Glycotex under clause
     3.7, Novogen Laboratories must render to Glycotex a written invoice setting
     out the volume of Compound manufactured, packed and supplied to Glycotex
     pursuant to the Purchase Order, and the Purchase Price.

5.3  TIME FOR PAYMENT

     Glycotex must pay to Novogen Laboratories the amount stated on each invoice
     correctly rendered under clause 5.2, within 14 Business Days of the date of
     the invoice.

5.4  REVIEWS OF THE PURCHASE PRICE

     Novogen Laboratories may review and adjust the Purchase Price once each
     Quarter in accordance with clause 5.5.

5.5  ADJUSTMENT OF PURCHASE PRICE

     In any Quarterly review under clause 5.4, the Purchase Price will be
     adjusted by reference to the actual component costs of the Purchase Price
     for the preceding Quarter, and any adjustment will be effective for all
     Purchase Orders made after written notice by Novogen Laboratories to
     Glycotex of that adjustment.

                                                                             10.
<PAGE>
5.6  SUSPENSION OF SUPPLY

     If Glycotex does not pay any amount due in accordance with this clause 5,
     Novogen Laboratories may suspend the supply of any further Compound to
     Glycotex until payment is made.

5.7  INSPECTION

     Glycotex may during normal business hours and upon reasonable notice by its
     authorised representatives (including accountants and auditors) inspect the
     records and books of account of Novogen Laboratories to determine whether
     the Purchase Price has been calculated in accordance with this document.
     Such authorised representatives may take such copies and extracts of the
     records and books of account as they think fit and Novogen Laboratories
     must, and must ensure that its agents and contractors, give those
     authorised representatives such assistance as is necessary (including by
     providing access to facilities, hardware, software and documents) to enable
     the Purchase Price to be ascertained or verified.

6.   PAYMENT TERMS

6.1  PAYMENTS

     All amounts due and payable under clause 5 must be calculated and paid in
     United States dollars and must be paid by bank cheque or electronic
     transfer to an account notified by Novogen Laboratories in writing.

6.2  INTEREST ON OVERDUE ACCOUNTS

     Interest shall accrue at the Default Rate on the outstanding balance of all
     overdue amounts payable under clause 5, calculated daily.

6.3  TERMINATION

     At the end of the Term the price for all Compound delivered to Glycotex
     becomes immediately due and payable to Novogen Laboratories, despite any
     other payment terms in this document.

7.   GOODS AND SERVICES TAX

7.1  GST LAW DEFINITIONS

     Words defined in the GST Law have the same meaning in this clause 7, unless
     the context makes it clear that a different meaning is intended.

7.2  GST PAYABLE IN ADDITION TO OTHER AMOUNTS

     In addition to paying all amounts payable by Glycotex under this document,
     Glycotex must:

     (a)  pay to Novogen Laboratories an amount equal to any GST payable on any
          supply by Novogen Laboratories under or in connection with this
          document without deduction or set-off of any other amount;

                                                                             11.
<PAGE>
     (b)  make that payment:

          (i)  if Novogen Laboratories must pay GST on or after receiving the
               consideration or any part of it - as and when Glycotex must pay
               or provide the consideration or that part of it;

          (ii) if Novogen Laboratories must pay GST on issuing an invoice under
               this document - on the earlier of the due date for payment of
               that invoice, or 10 Business Days following the end of the month
               in which Novogen Laboratories issued that invoice; and

          (iii) if Novogen Laboratories must pay GST upon the occurrence of some
               other event - within 5 Business Days of a written request by
               Novogen Laboratories for payment for the GST, which may be in the
               form of a tax invoice (or an adjustment note); and

     (c)  indemnify Novogen Laboratories against, and pay Novogen Laboratories
          on demand the amount of:

          (i)  all GST on the transactions contemplated by this document; and

          (ii) any loss, liability or expense directly or indirectly incurred in
               connection with or arising from or caused by any failure by
               Glycotex to pay any amount as and when required by this clause 7,
               for example, any additional tax, penalty tax, fine, interest or
               other charge under a GST Law.

7.3  TAX INVOICE

     Within 28 days of a written request from Glycotex, Novogen Laboratories
     must issue a tax invoice (or an adjustment note) to Glycotex for any supply
     for which Novogen Laboratories may recover GST from Glycotex under this
     document, and must include in the tax invoice (or adjustment note) the
     particulars required by the GST Law for Glycotex to obtain an input tax
     credit for that GST.

7.4  ADJUSTMENTS

     Novogen Laboratories must refund to Glycotex any overpayment by Glycotex
     for GST, but Novogen Laboratories need not refund to Glycotex any amount
     for GST paid to the Commissioner of Taxation unless Novogen Laboratories
     has received a refund or credit of that amount.

7.5  GST WHERE GLYCOTEX SUPPLIES NOVOGEN LABORATORIES

     If Glycotex must pay GST for anything provided or supplied by Glycotex
     under this document, Novogen Laboratories must pay to Glycotex an amount
     equal to that GST in exactly the same way as Glycotex must so do for any
     GST Novogen Laboratories must pay, and this clause 7 applies to that GST as
     if Glycotex was Novogen Laboratories, and Novogen Laboratories was
     Glycotex.

                                                                             12.
<PAGE>
8.   MANUFACTURING DEVELOPMENTS AND IMPROVEMENTS

8.1  MANUFACTURING DEVELOPMENTS

     Glycotex shall disclose to Novogen Laboratories all Manufacturing
     Developments as soon as is reasonably practicable after becoming aware of
     them.

8.2  MANUFACTURING IMPROVEMENTS

     Novogen Laboratories shall disclose to Glycotex all Manufacturing
     Improvements immediately upon becoming aware of them, and by this document
     Novogen Laboratories assigns to Glycotex absolutely and as beneficial owner
     its entire right, title to and interest in all Intellectual Property Rights
     in Manufacturing Improvements.

8.3  TECHNICAL ASSISTANCE

     Glycotex shall promptly supply to Novogen Laboratories such technical
     information and assistance as Novogen Laboratories may reasonably request
     during the Term in order to exercise its rights and perform its obligations
     under this document.

9.   INTELLECTUAL PROPERTY RIGHTS

9.1  ACKNOWLEDGMENT

     Each party acknowledges that nothing in this document effects an assignment
     or transfer to Novogen Laboratories of any right, title or interest in the
     Licensed Intellectual Property and Novogen Laboratories must not represent
     that it has any right, title or interest in the Licensed Intellectual
     Property, other than the rights expressly granted to it under this
     document.

9.2  NOTIFICATION

     Novogen Laboratories shall notify Glycotex immediately upon becoming aware
     of:

     (a)  any actual or apparent infringement by any person of any Intellectual
          Property Rights in the Licensed Intellectual Property; or

     (b)  any assertion or claim by any person that the activities of a party
          under this document infringe the Intellectual Property Rights of any
          person.

9.3  JOINDER OF NOVOGEN LABORATORIES

     If it is necessary that Novogen Laboratories be a party to any proceedings
     commenced by Glycotex for infringement of the Licensed Intellectual
     Property, Novogen Laboratories shall join such proceedings as a plaintiff
     and shall at Glycotex's cost provide all reasonable assistance, and execute
     any documents Glycotex reasonably requests, in relation to the proceedings.

                                                                             13.
<PAGE>
10.  CONFIDENTIAL INFORMATION

10.1 CONFIDENTIALITY

     Novogen Laboratories shall:

     (a)  keep and maintain all Confidential Information strictly confidential;

     (b)  use Confidential Information only for the purposes for which it is
          disclosed; and

     (c)  not disclose Confidential Information other than to its employees,
          authorised sub-contractors, legal advisers, auditors or other
          consultants requiring the information for the purposes of this
          document and then only upon those persons undertaking in writing to
          keep that information strictly confidential.

10.2 SECURITY

     For the purposes of clause 10.1, Novogen Laboratories shall establish and
     maintain effective security measures to safeguard the Confidential
     Information from unauthorised use or access and shall notify Glycotex
     immediately upon becoming aware of any suspected or actual unauthorised use
     or disclosure of the Confidential Information.

10.3 EXCEPTIONS TO OBLIGATIONS OF CONFIDENTIALITY

     The obligations in clauses 10.1 and 10.2 do not apply to the extent that
     Novogen Laboratories is required by law to disclose the Confidential
     Information, provided that it promptly gives notice to Glycotex of that
     requirement and discloses only that part of the Confidential Information
     which it is legally required to disclose.

10.4 PUBLIC DOMAIN

     No Confidential Information shall be deemed to be in the public domain
     merely because it contains information which is in the public domain or is
     embraced by a general disclosure which is in the public domain.

11.  REPRESENTATIONS AND WARRANTIES

11.1 WARRANTIES OF EACH PARTY

     Each party represents and warrants that:

     (a)  (POWER) it has full legal capacity and power to:

          (i)  own its property and to carry on its business; and

          (ii) enter into this document and to carry out the transactions that
               this document contemplates;

     (b)  (CORPORATE AUTHORITY) it has taken all corporate action that is
          necessary or desirable to authorise its entry into this document and
          its carrying out the transactions that this document contemplates;

                                                                             14.
<PAGE>
     (c)  (DOCUMENTS EFFECTIVE) this document constitutes its legal, valid and
          binding obligations, enforceable against it in accordance with its
          terms (except to the extent limited by equitable principles and laws
          affecting creditors' rights generally), subject to any necessary
          stamping or registration;

     (d)  (NO CONTRAVENTION) neither its execution of this document nor the
          carrying out by it of the transactions that this document
          contemplates, does or will:

          (i)  contravene any law to which it or any of its property is subject
               or any order of any Government Agency that is binding on it or
               any of its property;

          (ii) contravene any undertaking or instrument binding on it or any of
               its property;

          (iii) contravene its constitution; or

          (iv) require it to make any payment or delivery in respect of any
               financial indebtedness before it would otherwise be obliged to do
               so; and

     (e)  (NO TRUST) it is not entering into this document as trustee of any
          trust or settlement.

11.2 REPRESENTATIONS AND WARRANTIES BY NOVOGEN LABORATORIES

     Novogen Laboratories represents and warrants to Glycotex at the time title
     to any Compound passes from Novogen Laboratories to Glycotex under clause
     4, that:

     (a)  (OWNERSHIP) Novogen Laboratories is the legal and beneficial owner of
          the Compound and no other person has or shall have any right, title or
          interest in or in relation to the Compound;

     (b)  (NO ENCUMBRANCE) the Compound is free from any Encumbrance; and

     (c)  (QUALITY) the Compound is of merchantable quality and is fit for the
          purpose for which it is intended to be used under this document.

11.3 RELIANCE ON REPRESENTATIONS AND WARRANTIES

     Each party acknowledges that the other party has executed this document and
     agreed to take part in the transactions that this document contemplates in
     reliance on the representations and warranties that are made in this clause
     11.

11.4 EXCLUSION OF CONDITIONS AND WARRANTIES

     Except for the warranties expressly made in this document, all conditions,
     warranties, undertakings or representations express or implied arising by
     statute, general law or otherwise are expressly excluded to the extent
     permitted by law.

                                                                             15.
<PAGE>
12.  LIMITATION OF LIABILITY

12.1 INDIRECT AND CONSEQUENTIAL LOSS

     Despite any other provision of this document, and to the extent permitted
     by law, in no circumstances is Novogen Laboratories liable in contract,
     tort (including negligence or breach of statutory duty) or otherwise, and
     whatever the cause, to compensate Glycotex for:

     (a)  any increased costs or expenses;

     (b)  any economic loss, loss of profit, revenue, business, contracts or
          anticipated savings; or

     (c)  any other special, indirect or consequential loss or damage of any
          nature.

12.2 STATUTORY WARRANTIES

     If legislation implies in this document any condition or warranty and that
     legislation avoids or prohibits provisions in a contract excluding or
     modifying the application of or exercise of or liability under such
     condition or warranty, the condition or warranty shall be deemed to be
     included in this document. However the liability of Novogen Laboratories
     for any breach of such condition or warranty shall be limited at the option
     of Novogen Laboratories to one or more of the following:

     (a)  if the breach relates to goods:

          (i)  the replacement of the goods or the supply of equivalent goods;

          (ii) the repair of the goods;

          (iii) the payment of the cost of replacing the goods or of acquiring
               equivalent goods; or

          (iv) the payment of the cost of having the goods repaired; and

     (b)  if the breach relates to services:

          (i)  the supplying of the services again; or

          (ii) the payment of the cost of having the services supplied again.

12.3 BARRING OF CLAIMS FOR QUANTITY SHORTFALLS OR DAMAGE

     To the extent permitted by law, Glycotex may not bring any claim of any
     kind for shortfalls or physical damage to any Compound in a delivery unless
     Glycotex has given notice in writing to Novogen Laboratories setting out
     details of that damage within 10 Business Days after the receipt of the
     delivery.

                                                                             16.
<PAGE>
12.4 BARRING OF CLAIMS FOR DEFECTS IN QUALITY

     To the extent permitted by law, Glycotex may not bring any claim of any
     kind in respect of any breach of the warranty in clause 11.2(c) unless
     Glycotex has given notice in writing to Novogen Laboratories setting out
     details of that breach within 5 Business Days after Glycotex becomes aware
     of the breach.

13.  INDEMNITIES AND INSURANCE

13.1 CLINICAL TRIAL INDEMNITY

     Glycotex must indemnify and keep indemnified Novogen Laboratories, its
     directors, employees and agents against all damages, costs or expenses
     (including legal costs and expenses on an indemnity basis) in respect of
     any claims, demands, actions, proceedings or prosecution which may be
     brought or commenced as a result of or in relation to:

     (a)  the conduct of Clinical Trials generally; or

     (b)  any personal injury to or death of any person enrolled in a Clinical
          Trial arising out of or relating to the administration of a Product or
          any clinical intervention or procedure during or as a result of a
          Clinical Trial,

     except to the extent that the claim, demand, action, proceeding or
     prosecution arose from any negligence (including breach of statutory duty)
     of Novogen Laboratories or any breach by Novogen Laboratories of its
     obligations under this document.

13.2 COMMERCIALISATION INDEMNITY

     Glycotex must indemnify and keep indemnified Novogen Laboratories, its
     directors, employees and agents against all damages, costs or expenses
     (including legal costs and expenses on an indemnity basis) in respect of
     any claims, demands, actions, proceedings or prosecution which may be
     brought or commenced as a result of or in relation to:

     (a)  the sale, distribution or other commercialisation or exploitation of
          Products; or

     (b)  any packaging, marketing, advertisement or promotion of Products,

     by Glycotex, its employees, agents, contractors and sub-licensees,
     including any warranty claims, product liability claims, product recalls
     and claims for personal injury or property damage, except to the extent
     that the claim, demand, action, proceeding or prosecution arose from the
     negligence (including breach of statutory duty) of Novogen Laboratories or
     the breach by Novogen Laboratories of its obligations under this document.

13.3 GLYCOTEX'S INSURANCE POLICIES

     Glycotex must take out and maintain in force in the Territory comprehensive
     general liability insurance, including advertising and product liability
     insurance, for personal injury and property damage and product recall
     insurance, in relation to all Products on terms satisfactory to Novogen
     Laboratories.

                                                                             17.
<PAGE>
13.4 NAME OF NOVOGEN LABORATORIES

     If requested by Novogen Laboratories, Glycotex must ensure that that
     Novogen Laboratories is included on the policies referred to in clause 13.3
     as a joint insured or loss payee.

13.5 CERTIFICATES OF CURRENCY

     At the request of Novogen Laboratories from time to time, Glycotex must
     provide to Novogen Laboratories a certificate of currency evidencing its
     compliance with its obligations under this clause 13.

13.6 DEFAULT

     If within 15 Business Days of a request by Novogen Laboratories under
     clause 13.5, Glycotex does not comply with its obligations under that
     clause, Novogen Laboratories may (but is not obliged to) take out and
     maintain the insurance and may recover any premiums paid as a debt due by
     Glycotex.

13.7 EXPIRY

     Glycotex shall maintain each insurance policy referred to in clause 13.3
     until the expiry date of the last Product sold, hired or otherwise disposed
     of by or on behalf of Glycotex or its sub-licensees.

13.8 NOVOGEN LABORATORIES' INSURANCE

     Novogen Laboratories must take out and maintain in force in the Territory
     comprehensive general liability insurance policies in relation to its
     obligations under this document on terms reasonably satisfactory to
     Glycotex.

14.  FORCE MAJEURE

14.1 NOTICE AND SUSPENSION OF OBLIGATIONS

     If a party to this document is affected, or likely to be affected, by a
     Force Majeure Event:

     (a)  that party must immediately give the other prompt notice of that fact
          including:

          (i)  full particulars of the Force Majeure Event;

          (ii) an estimate of its likely duration;

          (iii) the obligations affected by it and the extent of its effect on
               those obligations; and

          (iv) the steps taken to rectify it; and

     (b)  the obligations under this document of the party giving the notice are
          suspended to the extent to which they are affected by the relevant
          Force Majeure Event as long as the Force Majeure Event continues.

                                                                             18.
<PAGE>
14.2 EFFORT TO OVERCOME

     A party claiming a Force Majeure Event must use its best endeavours to
     remove, overcome or minimise the effects of that Force Majeure Event as
     quickly as possible. However, this does not require a party to settle any
     industrial dispute in any way it does not want to.

14.3 TERMINATION

     If a Force Majeure Event continues for more than 3 months, any party may
     terminate this document by giving at least 10 Business Days notice to the
     other party.

15.  TERM AND TERMINATION

15.1 TERM

     The rights and obligations of the parties under this document begin on the
     Commencement Date and continue until this document is terminated in
     accordance with this clause 15.

15.2 TERMINATION BY GLYCOTEX

     Glycotex may terminate this document at any time:

     (a)  immediately by notice in writing at any time if the Licence Agreement
          expires or is terminated for any reason;

     (b)  immediately if Novogen Laboratories defaults in the performance of any
          of its obligations under this document which in Glycotex's reasonable
          opinion is capable of remedy and fails to remedy that default within
          21 days of receiving written notice from Glycotex specifying the
          default and requiring the default to be remedied;

     (c)  on 21 days written notice if Novogen Laboratories defaults in the
          performance of any of its material obligations under this document
          which in Glycotex's reasonable opinion is not capable of remedy;

     (d)  immediately by notice in writing if:

          (i)  Novogen Laboratories is involved in an Insolvency Event; or

          (ii) Novogen Laboratories ceases for any reason to be able lawfully to
               carry out all the transactions which this document contemplates
               may be carried out by Novogen Laboratories; and

     (e)  immediately by notice in writing without cause if:

          (i)  it has given Novogen Laboratories 90 days' written notice; and

          (ii) it has paid to Novogen Laboratories an amount of US$250,000
               (which amount Glycotex acknowledges is a reasonable pre-estimate
               of the loss that Novogen Laboratories is likely to suffer if
               Glycotex terminates this document without cause under this
               paragraph).

                                                                             19.
<PAGE>
15.3 TERMINATION BY NOVOGEN LABORATORIES

     Novogen Laboratories may terminate this document at any time:

     (a)  immediately if Glycotex defaults in the performance of any of its
          obligations under this document which in Novogen Laboratories'
          reasonable opinion is capable of remedy and fails to remedy that
          default within 21 days of receiving written notice from Novogen
          Laboratories specifying the default and requiring the default to be
          remedied;

     (b)  on 21 days written notice if Glycotex defaults in the performance of
          any of its material obligations under this document which in Novogen
          Laboratories' reasonable opinion is not capable of remedy; and

     (c)  immediately by notice in writing if:

          (i)  there is a Change in Control of Glycotex without Novogen
               Laboratories' written consent;

          (ii) Glycotex is involved in an Insolvency Event; or

          (iii) Glycotex ceases for any reason to be able lawfully to carry out
               all the transactions which this document contemplates may be
               carried out by Glycotex.

15.4 CONSEQUENCES OF TERMINATION

     Upon expiration or termination of this document for any reason Novogen
     Laboratories must deliver to Glycotex or destroy at Glycotex's election,
     all Compound and Confidential Information in Novogen Laboratories'
     possession, custody or power and the provisions of clauses 5, 6 and 7 shall
     apply with respect to that Compound.

15.5 SURVIVAL AND ACCRUED RIGHTS

     Upon termination under this clause 15, this document is at an end as to its
     future operation except for:

     (a)  the enforcement of any right or claim which arises on or has arisen
          before termination; and

     (b)  the obligations of the parties under clauses 1, 6.3, 7, 10, 11.4, 12,
          13, 16, 17, 18, 19 (except clause 19.4) and this clause 15, which
          survive termination.

16.  DISPUTE RESOLUTION

16.1 DISPUTES

     If a dispute arises out of or in relation to this document (including any
     dispute as to breach or termination of the document or as to any claim in
     tort, in equity or pursuant to any statute) (a DISPUTE), a party to this
     document may not commence any court or arbitration proceedings relating to
     the Dispute unless it has complied with this clause 16 except where the
     party seeks urgent interlocutory relief.

                                                                             20.
<PAGE>
16.2 NOTICE OF DISPUTE

     A party to this document claiming that a Dispute has arisen under or in
     relation to this document must give written notice to the other party
     specifying the nature of the Dispute (a DISPUTE NOTICE).

16.3 NEGOTIATION

     Upon receipt by a party of a Dispute Notice, Novogen Laboratories and
     Glycotex must procure that their respective Managing Directors meet to
     endeavour to resolve the Dispute expeditiously by negotiation.

16.4 RESOLUTION OF DISPUTE

     If the parties have not resolved the Dispute under clause 16.3 within 14
     days of receipt of a Dispute Notice, the parties must endeavour to resolve
     the Dispute expeditiously using informal dispute resolution techniques such
     as mediation, expert evaluation or determination or similar techniques
     agreed by the parties.

16.5 MEDIATION

     If the parties do not agree within 28 days of receipt of a Dispute Notice
     (or such further period as the parties agree in writing) as to:

     (a)  the dispute resolution technique and procedures to be adopted;

     (b)  the timetable for all steps in those procedures; and

     (c)  the selection and compensation of the independent person required for
          such technique,

     the parties must mediate the Dispute in accordance with the Mediation Rules
     of the Law Society of New South Wales, and the President of the Law Society
     of New South Wales (or the President's nominee) will select the mediator
     and determine the mediator's remuneration.

17.  NOTICES

     (a)  A notice, consent or other communication under this document is only
          effective if it is in writing, signed and either left at the
          addressee's address or sent to the addressee by mail or fax. If it is
          sent by mail, it is taken to have been received 3 working days after
          it is posted. If it is sent by fax, it is taken to have been received
          when the addressee actually receives it in full and in legible form.

     (b)  The parties' addresses and fax numbers are those set out below, or as
          a party notifies the other:

          GLYCOTEX
          Address:      140 Wicks Road North Ryde, NSW 2113 AUSTRALIA
          Fax number:   Int + 612 9878 0055
          Attention:    The President

                                                                             21.
<PAGE>
          NOVOGEN LABORATORIES
          Address:      140 Wicks Road North Ryde, NSW 2113 AUSTRALIA
          Fax number:   Int + 612 9878 0055
          Attention:    Managing Director

18.  AMENDMENT AND ASSIGNMENT

18.1 AMENDMENT

     This document can only be amended, supplemented, replaced or novated by
     another document signed by the parties.

18.2 ASSIGNMENT

     A party may only dispose of, declare a trust over or otherwise create an
     interest in its rights under this document with the other party's consent.

19.  GENERAL

19.1 GOVERNING LAW

     (a)  This document is governed by the law in force in New South Wales,
          Australia.

     (b)  Each party submits to the non-exclusive jurisdiction of the courts
          exercising jurisdiction in New South Wales, and any court that may
          hear appeals from any of those courts, for any proceedings in
          connection with this document, and waives any right it might have to
          claim that those courts are an inconvenient forum.

19.2 LIABILITY FOR EXPENSES

     Each party must pay its own expenses incurred in negotiating, executing,
     stamping and registering this document.

19.3 RELATIONSHIP OF THE PARTIES

     Nothing in this document creates a relationship of employment, partnership
     or joint venture between the parties under the laws of any applicable
     jurisdiction and no party may act or has the authority to act as agent of
     or in any way bind or commit another party to any obligation.

19.4 GIVING EFFECT TO THIS DOCUMENT

     Each party must do anything (including execute any document), and must
     ensure that its employees and agents do anything (including execute any
     document), that the other party may reasonably require to give full effect
     to this document.

                                                                             22.
<PAGE>
19.5 WAIVER OF RIGHTS

     A right may only be waived in writing, signed by the party giving the
     waiver, and:

     (a)  no other conduct of a party (including a failure to exercise, or delay
          in exercising, the right) operates as a waiver of the right or
          otherwise prevents the exercise of the right;

     (b)  a waiver of a right on one or more occasions does not operate as a
          waiver of that right if it arises again; and

     (c)  the exercise of a right does not prevent any further exercise of that
          right or of any other right.

19.6 OPERATION OF THIS DOCUMENT

     (a)  This document contains the entire document between the parties about
          its subject matter. Any previous understanding, document,
          representation or warranty relating to that subject matter is replaced
          by this document and has no further effect.

     (b)  Any right that a person may have under this document is in addition
          to, and does not replace or limit, any other right that the person may
          have.

     (c)  Any provision of this document which is unenforceable or partly
          unenforceable is, where possible, to be severed to the extent
          necessary to make this document enforceable, unless this would
          materially change the intended effect of this document.

19.7 EXCLUSION OF CONTRARY LEGISLATION

     Any legislation that adversely affects an obligation of a party, or the
     exercise by a party of a right or remedy, under or relating to this
     document is excluded to the full extent permitted by law.

19.8 COUNTERPARTS

     This document may be executed in counterparts.

                                                                             23.
<PAGE>
EXECUTED as an agreement.

EXECUTED by GLYCOTEX, INC.:

/s/ David Seaton                         /s/ David Seaton
--------------------------------------   ---------------------------------------
Signature of director                    Signature of director/secretary

DAVID SEATON                             DAVID SEATON
--------------------------------------   ---------------------------------------
Name                                     Name

EXECUTED by NOVOGEN RESEARCH PTY
LIMITED:

/s/ Christopher Naughton                 /s/ Ron Lea Erratt
--------------------------------------   ---------------------------------------
Signature of director                    Signature of director/secretary

CHRISTOPHER NAUGHTON                     RON LEA ERRATT
--------------------------------------   ---------------------------------------
Name                                     Name

                                                                             24.
<PAGE>
                                   SCHEDULE 1

                              GLUCAN PATENT RIGHTS

<TABLE>
<CAPTION>
COUNTRY              NO.              PRIORITY        STATUS
------------------   --------------   -------------   -----------------
<S>                  <C>              <C>             <C>
PCT                  PCT/AU96/00138   13 March 1995   Filed
Australia            716181           13 March 1995   Granted
Canada               2 214 899        13 March 1995   Under examination
Europe               0815144          13 March 1995   Granted
Japan                08-527114        13 March 1995   Pending
UK                   2331014          13 March 1995   Granted
UK (divisional)      2314850          13 March 1995   Granted
USA                  6242594          13 March 1995   Granted
USA (continuation)   10/421,659       13 March 1995   Under examination
</TABLE>

                                                                             25.<PAGE>
                                                                    Exhibit 10.3

                                                            BLAKE DAWSON WALDRON
                                                                   LAWYERS

                    AMENDED AND RE-STATED SERVICES AGREEMENT

                                 NOVOGEN LIMITED
                               ABN 37 063 259 754

                                 GLYCOTEX, INC.

                                Level 35
                       225 George Street
                         SYDNEY NSW 2000
              Telephone: +61 2 9258 6000
                    Fax: +61 2 9258 6999   REF: BLM SJH 02 1389 1453

                          (C) BLAKE DAWSON WALDRON 2005
<PAGE>
                                    CONTENTS
<TABLE>
<S>                                                                           <C>
1.   INTERPRETATION                                                            1

     1.1  Definitions                                                          1
     1.2  Rules for interpreting this document                                 4
     1.3  Business Days                                                        5

2.   APPOINTMENT                                                               5

     2.1  Appointment                                                          5
     2.2  Nature of appointment                                                5

3.   NOVOGEN'S OBLIGATIONS                                                     5

     3.1  Services                                                             5
     3.2  Sub-contracting and consultants                                      6
     3.3  Appropriate personnel                                                6
     3.4  Performance of the Services                                          6
     3.5  Judgment and skill                                                   6

4.   FEES FOR SERVICES                                                         7

     4.1  Consideration for Services                                           7
     4.2  Invoices                                                             7
     4.3  Payment of invoices                                                  7
     4.4  Payments                                                             7
     4.5  Amendment of the Agreed Budget                                       7
     4.6  Inspection of records                                                7

5.   GOODS AND SERVICES TAX                                                    8

     5.1  GST Law definitions                                                  8
     5.2  GST payable in addition to other amounts                             8
     5.3  Tax invoice                                                          8
     5.4  Adjustments                                                          9
     5.5  GST where Glycotex supplies Novogen                                  9

6.   MATERIALS AND INTELLECTUAL PROPERTY RIGHTS                                9

     6.1  Materials and information                                            9
     6.2  Intellectual Property Rights                                         9
     6.3  Acknowledgment                                                       9

7.   CONFIDENTIAL INFORMATION                                                  9

     7.1  Confidentiality                                                      9
     7.2  Security                                                            10
     7.3  Exceptions to obligations of confidentiality                        10
</TABLE>
<PAGE>
<TABLE>
<S>                                                                           <C>
     7.4  Public domain                                                       10

8.   REPRESENTATIONS AND WARRANTIES                                           10

     8.1  Representations and warranties                                      10
     8.2  Reliance on representations and warranties                          11
     8.3  Exclusion of conditions and warranties                              11
     8.4  Statutory warranties                                                11

9.   DISPUTE RESOLUTION                                                       12

     9.1  Dispute resolution                                                  12
     9.2  Dispute Notice                                                      12
     9.3  Negotiation                                                         12
     9.4  Resolution of Disputes                                              12
     9.5  Mediation                                                           12

10.  TERM AND TERMINATION                                                     12

     10.1 Term                                                                12
     10.2 Termination by Glycotex                                             13
     10.3 Termination by Novogen                                              13
     10.4 Consequences of termination                                         14
     10.5 Survival and accrued rights                                         14

11.  FORCE MAJEURE                                                            14

     11.1 Notice and suspension of obligations                                14
     11.2 Effort to overcome                                                  14
     11.3 Termination                                                         15

12.  NOTICES                                                                  15

13.  AMENDMENT AND ASSIGNMENT                                                 15

     13.1 Amendment                                                           15
     13.2 Assignment                                                          15

14.  GENERAL                                                                  15

     14.1 Governing law                                                       15
     14.2 Liability for expenses                                              16
     14.3 Giving effect to this document                                      16
     14.4 Waiver of rights                                                    16
     14.5 Operation of this document                                          16
     14.6 Operation of indemnities                                            16
     14.7 Consents                                                            17
     14.8 Exclusion of contrary legislation                                   17
     14.9 Counterparts                                                        17
</TABLE>

                                                                             ii.
<PAGE>
<TABLE>
<S>                                                                           <C>
SCHEDULE 1: CALCULATION OF FEES FOR SERVICES                                  18

ANNEXURE A: AGREED BUDGET                                                     21
</TABLE>

                                                                            iii.
<PAGE>
                    AMENDED AND RE-STATED SERVICES AGREEMENT

DATE September 2005

PARTIES

     NOVOGEN LIMITED ABN 37 063 259 754 (NOVOGEN)

     GLYCOTEX, INC., a company incorporated under the laws of Delaware, United
     States of America, c/- 1 Landmark Square, Suite 240, Stamford Connecticut
     06901, USA (GLYCOTEX)

RECITALS

A.   Novogen has certain skills and expertise in relation to the discovery,
     research and development of human therapeutics and their commercialisation.

B.   Glycotex engaged Novogen to perform the Services on the terms and
     conditions of a Services Agreement dated 30 April 2003.

C.   The parties now amend and re-state the Services Agreement on the terms and
     conditions of this document.

OPERATIVE PROVISIONS

1.   INTERPRETATION

1.1  DEFINITIONS

     The following definitions apply in this document.

     AGREED BUDGET means the budget agreed in accordance with schedule 1 and
     attached as Annexure A.

     AUTHORISATION means:

     (a)  an authorisation, consent, declaration, exemption, notarisation or
          waiver, however it is described; and

     (b)  in relation to anything that could be prohibited or restricted by law
          if a Government Agency acts in any way within a specified period, the
          expiry of that period without that action being taken,

     including any renewal or amendment.

     BUSINESS DAY means a day that is not a Saturday, Sunday or public holiday
     in Sydney, Australia.

     CHANGE IN CONTROL, in relation to Glycotex means:

     (a)  the acquisition by any Person or Group other than Novogen Limited of
          more than 50% of the combined voting power of the then outstanding
          securities entitled to vote generally in the election of directors of
          Glycotex; or
<PAGE>
     (b)  any merger, consolidation, reorganization, recapitalization, tender or
          exchange offer or any other transaction with or effecting Glycotex as
          a result of which a Person or Group other than the stockholders of
          Glycotex immediately before the transaction owns after the transaction
          more than 50% of the combined voting power of the then outstanding
          securities entitled to vote generally in the election of the directors
          of Glycotex,

     but does not include any acquisition as a result of, or transaction
     involving, an initial public offering of Glycotex's common stock.

     COMMENCEMENT DATE means the date this document is executed by the last of
     the parties to execute it.

     COMMONWEALTH means the Commonwealth of Australia.

     CONFIDENTIAL INFORMATION in relation to a party means all information and
     materials disclosed, provided or otherwise made accessible to, or developed
     by that party whether before or after execution of this document, including
     all Know-How, financial reports, sales information, policies, plans,
     business affairs, transactions, organisations, business connections and
     clients of that party, and any other information which that party
     reasonably considers confidential, but excludes information which the other
     party can establish:

     (a)  was in the public domain at the date of this document;

     (b)  after the date of this document, became part of the public domain
          otherwise than as a result of disclosure directly or indirectly in
          breach of this document; or

     (c)  was in its possession at the time of disclosure and was not otherwise
          acquired from the other party directly or indirectly.

     CORPORATIONS ACT means the Corporations Act 2001 (Cth).

     DISPUTE has the meaning given to that term in clause 9.1.

     DISPUTE NOTICE has the meaning given to that term in clause 9.2.

     ENCUMBRANCE means a mortgage, charge, pledge, lien, hypothecation or title
     retention arrangement, a right of set-off or right to withhold payment of a
     deposit or other money, a notice under section 255 of the Income Tax
     Assessment Act 1936 (Cth), section 260-5 in schedule 1 to the Taxation
     Administration Act 1953 (Cth) or any similar legislation, or an easement,
     restrictive covenant, caveat or similar restriction over property, or an
     agreement to create any of them or to allow any of them to exist.

     FORCE MAJEURE EVENT means any occurrence or omission as a direct or
     indirect result of which the party relying on it is prevented from or
     delayed in performing any of its obligations (other than a payment
     obligation) under this document and that is beyond the reasonable control
     of that party, including forces of nature, industrial action and action or
     inaction by a Government Agency.

                                                                              2.
<PAGE>
     GLYCOTEX PRODUCT means any human therapeutic or pharmaceutical compound,
     and any product or formulation containing any such compound, in relation to
     which Glycotex or its subsidiaries has Intellectual Property Rights,
     including the Licensed Products.

     GOVERNMENT AGENCY means:

     (a)  a government or government department or other body;

     (b)  a governmental, semi-governmental or judicial person; or

     (c)  a person (whether autonomous or not) who is charged with the
          administration of a law.

     GST means:

     (a)  the same as in the GST Law; and

     (b)  any other goods and services tax, or any tax applying to this
          transaction in a similar way; and

     (c)  any additional tax, penalty tax, fine, interest or other charge under
          a law for such a tax.

     GST LAW means the same as "GST law" means in A New Tax System (Goods and
     Services Tax) Act 1999 (Cth).

     INSOLVENCY EVENT means, for a person, being in liquidation or provisional
     liquidation or under administration, having a controller or analogous
     person appointed to it or any of its property, being taken to have failed
     to comply with a statutory demand, being unable to pay its debts or
     otherwise insolvent, dying, ceasing to be of full legal capacity or
     otherwise becoming incapable of managing its own affairs for any reason,
     taking any step that could result in the person becoming an insolvent under
     administration, entering into a compromise or arrangement with, or
     assignment for the benefit of, any of its members or creditors, or any
     analogous event.

     INTELLECTUAL PROPERTY RIGHTS means any and all existing and future
     intellectual and industrial property rights throughout the world, whether
     conferred by statute, common law or equity, including rights in relation to
     copyright, trade marks, designs, circuit layouts, plant varieties, business
     and domain names, trade secrets and Know How (including the right to apply
     for registration of any such rights), Patent Rights and other results of
     intellectual activity in the industrial, commercial, scientific, literary
     or artistic fields.

     KNOW HOW means technical and other information which is not in the public
     domain including inventions, discoveries, concepts, data, formulae, ideas,
     specifications, procedures for experiments and tests, results of
     experimentation and testing, results of research and development and
     information in laboratory records, data collected during the course of
     clinical trials, case reports, data analyses and summaries and submissions
     to and information from ethics committees and regulatory authorities.

                                                                              3.
<PAGE>
     LICENCE AGREEMENT means the document entitled "Amended and Re-stated
     Technology Licence Agreement" between Novogen Research and Glycotex, dated
     on or about the date of this document.

     LICENSED PRODUCT has the meaning given to it in the Licence Agreement.

     NOVOGEN RESEARCH means Novogen Research Pty Limited.

     PATENT RIGHTS means existing and future patents (including any divisions,
     continuations, continuations in part, renewals, reissues, extensions,
     supplementary protection certificates, utility models and foreign
     equivalents thereof) and rights with respect to existing and future patent
     applications and patentable inventions, including the right to apply for
     registration of any such rights.

     QUARTER means, in respect of any calender year in the Term, the four
     quarters of that year, the first of which commences on the first day of
     that year.

     SERVICES means the services set out in clause 3.1 and any other services
     Novogen agrees to perform for Glycotex during the Term.

     TERM means the term of this document, as determined under clause 10.

1.2  RULES FOR INTERPRETING THIS DOCUMENT

     Headings are for convenience only, and do not affect interpretation. The
     following rules also apply in interpreting this document, except where the
     context makes it clear that a rule is not intended to apply.

     (a)  A reference to:

          (i)  legislation (including subordinate legislation) is to that
               legislation as amended, re-enacted or replaced, and includes any
               subordinate legislation issued under it;

          (ii) a document or agreement, or a provision of a document or
               agreement, is to that document, agreement or provision as
               amended, supplemented, replaced or novated;

          (iii) a party to this document or to any other document or agreement
               includes a permitted substitute or a permitted assign of that
               party;

          (iv) a person includes any type of entity or body of persons, whether
               or not it is incorporated or has a separate legal identity, and
               any executor, administrator or successor in law of the person;
               and

          (v)  anything (including a right, obligation or concept) includes each
               part of it.

     (b)  A singular word includes the plural, and vice versa.

     (c)  A word which suggests one gender includes the other genders.

                                                                              4.
<PAGE>
     (d)  If a word is defined, another part of speech has a corresponding
          meaning.

     (e)  If an example is given of anything (including a right, obligation or
          concept), such as by saying it includes something else, the example
          does not limit the scope of that thing.

     (f)  The word AGREEMENT includes an undertaking or other binding
          arrangement or understanding, whether or not in writing.

     (g)  The words SUBSIDIARY, HOLDING COMPANY and RELATED BODY CORPORATE have
          the same meanings as in the Corporations Act.

1.3  BUSINESS DAYS

     If the day on or by which a person must do something under this document is
     not a Business Day:

     (a)  if the act involves a payment that is due on demand, the person must
          do it on or by the next Business Day; and

     (b)  in any other case, the person must do it on or by the previous
          Business Day.

2.   APPOINTMENT

2.1  APPOINTMENT

     Glycotex agrees to engage Novogen to provide the Services and Novogen
     agrees to provide the Services to Glycotex, on the terms and conditions of
     this document.

2.2  NATURE OF APPOINTMENT

     (a)  Novogen's engagement to provide the Services is as an independent
          contractor. Nothing in this document is to be treated as creating a
          partnership or joint venture between the parties under the laws of any
          applicable jurisdiction.

     (b)  Except as expressly provided in this document, no party may act or has
          any authority to act as agent of or in any way bind or commit the
          other party to any obligation.

3.   NOVOGEN'S OBLIGATIONS

3.1  SERVICES

     Novogen shall perform the following services in accordance with this
     document as Glycotex reasonably requests from time to time during the Term,
     having regard to the Agreed Budget:

     (a)  Novogen shall assist and advise Glycotex and its subsidiaries
          generally on all aspects of research, development and
          commercialisation of Glycotex Products;

                                                                              5.
<PAGE>
     (b)  Novogen shall provide company secretarial, marketing, finance,
          logistics administrative and managerial support to Glycotex and its
          subsidiaries;

     (c)  Novogen shall plan, conduct, direct, monitor and supervise
          pre-clinical and clinical trials of Glycotex Products;

     (d)  Novogen shall provide scientific and technical advice on management of
          pre-clinical and clinical research programs undertaken by Glycotex and
          its subsidiaries in relation to Glycotex Products and shall manage
          such research programs; and

     (e)  Novogen shall provide to Glycotex and its subsidiaries access to
          records relating to, and persons involved in the research and
          development of Licensed Products and any clinical trials conducted or
          commenced before the Commencement Date.

3.2  SUB-CONTRACTING AND CONSULTANTS

     (a)  Novogen shall not, without the prior written consent of Glycotex,
          sub-contract the provision of any part of the Services to any person
          other than its subsidiaries (excluding Glycotex).

     (b)  If at any time during the Term any person is under any obligation to
          Novogen or its subsidiaries (other than Glycotex) to provide services
          or perform obligations to persons including Glycotex, which services
          or obligations include research, development or commercialisation of
          Glycotex Products, then Novogen shall procure that that person
          provides those services to Glycotex.

3.3  APPROPRIATE PERSONNEL

     Novogen shall ensure that its employees, agents and consultants and the
     employees, agents and consultants of its subsidiaries who provide the
     Services have appropriate qualifications and experience to provide the
     Services, having regard to the nature of the Services.

3.4  PERFORMANCE OF THE SERVICES

     Novogen shall perform the Services:

     (a)  diligently, competently and with reasonable care and skill;

     (b)  in compliance with all applicable laws and regulations; and

     (c)  in accordance with the reasonable directions of Glycotex and its
          subsidiaries from time to time during the Term.

3.5  JUDGMENT AND SKILL

     Nothing in this clause 3 prevents Novogen from exercising its judgment and
     utilising its skills as it considers most appropriate to perform the
     Services.

                                                                              6.
<PAGE>
4.   FEES FOR SERVICES

4.1  CONSIDERATION FOR SERVICES

     In consideration of the performance by Novogen of the Services, Glycotex
     shall pay, in accordance with clause 4.3:

     (a)  services fees monthly in arrears in accordance with the Agreed Budget;
          and

     (b)  all reasonable out of pocket expenses (including travel and
          accommodation expenses) incurred by Novogen each month in the course
          of providing the Services.

4.2  INVOICES

     Within 7 days of the end of each month, Novogen shall each render to
     Glycotex a written invoice for payment for all Services provided by Novogen
     in that month, which shall contain the amount payable for the Services in
     that month calculated in accordance with schedule 1.

4.3  PAYMENT OF INVOICES

     Glycotex shall pay the amount of all correctly rendered invoices within 7
     days of the date of the invoice.

4.4  PAYMENTS

     All amounts due and payable under clause 4.3 must be calculated and paid in
     United States dollars and must be paid by bank cheque or electronic
     transfer to an account notified by Novogen in writing.

4.5  AMENDMENT OF THE AGREED BUDGET

     Each party shall inform the other party promptly upon becoming aware of any
     circumstance by virtue of which the estimates and assumptions on which the
     Agreed Budget was based are no longer accurate or applicable and the
     parties may amend the Agreed Budget by agreement from time to time during
     the Term having regard to any such circumstance.

4.6  INSPECTION OF RECORDS

     Glycotex may, during normal business hours and upon reasonable notice by
     its authorised representatives (including accountants and auditors),
     inspect the records and books of account of Novogen to determine whether
     the amounts paid or payable under this clause 4 have been calculated and
     paid in accordance with this clause 4, schedule 1 and the Agreed Budget.
     For the purposes of that inspection and determination, Glycotex's
     authorised representatives may take such copies and extracts of those
     records and books of account as they think fit and Novogen must, and must
     ensure that its agents and contractors, give Glycotex's authorised
     representatives such assistance as is necessary, including by providing
     access to facilities, hardware, software and documents, to enable that
     inspection and determination.

                                                                              7.
<PAGE>
5.   GOODS AND SERVICES TAX

5.1  GST LAW DEFINITIONS

     Words defined in the GST Law have the same meaning in this clause 5, unless
     the context makes it clear that a different meaning is intended.

5.2  GST PAYABLE IN ADDITION TO OTHER AMOUNTS

     In addition to paying all amounts payable by Glycotex under this document,
     Glycotex must:

     (a)  pay to Novogen an amount equal to any GST payable on any supply by
          Novogen under or in connection with this document without deduction or
          set-off of any other amount;

     (b)  make that payment:

          (i)  if Novogen must pay GST on or after receiving the consideration
               or any part of it - as and when Glycotex must pay or provide the
               consideration or that part of it;

          (ii) if Novogen must pay GST on issuing an invoice under this document
               - on the earlier of the due date for payment of that invoice, or
               10 Business Days following the end of the month in which Novogen
               issued that invoice; and

          (iii) if Novogen must pay GST upon the occurrence of some other event
               - within 5 Business Days of a written request by Novogen for
               payment for the GST, which may be in the form of a tax invoice
               (or an adjustment note); and

     (c)  indemnify Novogen against, and pay Novogen on demand the amount of:

          (i)  all GST on the transactions contemplated by this document; and

          (ii) any loss, liability or expense directly or indirectly incurred in
               connection with or arising from or caused by any failure by
               Glycotex to pay any amount as and when required by this clause 5,
               for example, any additional tax, penalty tax, fine, interest or
               other charge under a GST Law.

5.3  TAX INVOICE

     Within 28 days of a written request from Glycotex, Novogen must issue a tax
     invoice (or an adjustment note) to Glycotex for any supply for which
     Novogen may recover GST from Glycotex under this document, and must include
     in the tax invoice (or adjustment note) the particulars required by the GST
     Law for Glycotex to obtain an input tax credit for that GST.

                                                                              8.
<PAGE>
5.4  ADJUSTMENTS

     Novogen must refund to Glycotex any overpayment by Glycotex for GST, but
     Novogen need not refund to Glycotex any amount for GST paid to the
     Commissioner of Taxation unless Novogen has received a refund or credit of
     that amount.

5.5  GST WHERE GLYCOTEX SUPPLIES NOVOGEN

     If Glycotex must pay GST for anything provided or supplied by Glycotex
     under this document, Novogen must pay to Glycotex an amount equal to that
     GST in exactly the same way as Glycotex must so do for any GST Novogen must
     pay, and this clause 5 applies to that GST as if Glycotex was Novogen, and
     Novogen was Glycotex.

6.   MATERIALS AND INTELLECTUAL PROPERTY RIGHTS

6.1  MATERIALS AND INFORMATION

     Novogen acknowledges that all materials and information made available by
     Glycotex to Novogen in the performance of the Services remain the property
     of Glycotex.

6.2  INTELLECTUAL PROPERTY RIGHTS

     All Intellectual Property Rights created or developed by or on behalf of
     Novogen and its subsidiaries in the performance of the Services vest
     exclusively in Glycotex immediately upon their creation, and by this
     document Novogen assigns to Glycotex absolutely and as beneficial owner its
     entire right and title to and interest in all such Intellectual Property
     Rights.

6.3  ACKNOWLEDGMENT

     Novogen acknowledges that nothing in this document grants to it any
     Intellectual Property Rights created in the performance of the Services and
     Novogen must not, and must procure that its subsidiaries (other than
     Glycotex) do not, represent to any person that it or they have any such
     Intellectual Property Rights.

7.   CONFIDENTIAL INFORMATION

7.1  CONFIDENTIALITY

     Each party must:

     (a)  keep and maintain all Confidential Information of the other party
          strictly confidential;

     (b)  use Confidential Information of the other party only for the purposes
          for which it is disclosed; and

     (c)  not disclose any Confidential Information of the other party other
          than to its employees, authorised sub-contractors, legal advisers,
          auditors or other consultants requiring the information for the
          purposes of this document and then only upon those persons undertaking
          in writing to keep that information strictly confidential.

                                                                              9.
<PAGE>
7.2  SECURITY

     For the purposes of clause 7.1, each party must establish and maintain
     effective security measures to safeguard the Confidential Information of
     the other party from unauthorised use or access and must notify the other
     party immediately upon becoming aware of any suspected or actual
     unauthorised use or disclosure of that party's Confidential Information.

7.3  EXCEPTIONS TO OBLIGATIONS OF CONFIDENTIALITY

     The obligations in clauses 7.1 and 7.2 do not apply to the extent that a
     party is required by law to disclose the other party's Confidential
     Information, provided the party promptly gives notice to the other party of
     that requirement and discloses only that portion of Confidential
     Information which it is legally required to disclose.

7.4  PUBLIC DOMAIN

     No Confidential Information shall be deemed to be in the public domain
     merely because it contains information which is in the public domain or is
     embraced by a general disclosure which is in the public domain.

8.   REPRESENTATIONS AND WARRANTIES

8.1  REPRESENTATIONS AND WARRANTIES

     Each party represents and warrants that:

     (a)  (STATUS) it is a company limited by shares under the Corporations Act;

     (b)  (POWER) it has full legal capacity and power to:

          (i)  own its property and to carry on its business; and

          (ii) enter into this document and to carry out the transactions that
               this document contemplates;

     (c)  (CORPORATE AUTHORITY) it has taken all corporate action that is
          necessary or desirable to authorise its entry into this document and
          its carrying out the transactions that this document contemplates;

     (d)  (DOCUMENTS EFFECTIVE) this document constitutes its legal, valid and
          binding obligations, enforceable against it in accordance with its
          terms (except to the extent limited by equitable principles and laws
          affecting creditors' rights generally), subject to any necessary
          stamping or registration; and

     (e)  (NO CONTRAVENTION) neither its execution of this document nor the
          carrying out by it of the transactions that this document
          contemplates, does or will:

          (i)  contravene any law to which it or any of its property is subject
               or any order of any Government Agency that is binding on it or
               any of its property;

          (ii) contravene any Authorisation;

                                                                             10.
<PAGE>
          (iii) contravene any undertaking or instrument binding on it or any of
               its property;

          (iv) contravene its constitution; or

          (v)  require it to make any payment or delivery in respect of any
               financial indebtedness before it would otherwise be obliged to do
               so.

8.2  RELIANCE ON REPRESENTATIONS AND WARRANTIES

     Each party acknowledges that the other party has executed this document and
     agreed to take part in the transactions that this document contemplates in
     reliance on the representations and warranties that are made in clause 8.1.

8.3  EXCLUSION OF CONDITIONS AND WARRANTIES

     Except for the warranties expressly made in this document, all conditions,
     warranties, undertakings or representations express or implied arising by
     statute, general law or otherwise are expressly excluded to the extent
     permitted by law.

8.4  STATUTORY WARRANTIES

     If legislation implies in this document any condition or warranty and that
     legislation avoids of prohibits provisions in a contract excluding or
     modifying the application of or exercise of or liability under such
     condition or warranty, the condition or warranty shall be deemed to be
     included in this document. However the liability of Novogen for any breach
     of such condition or warranty shall be limited at the option of Novogen to
     one or more of the following:

     (a)  if the breach relates to goods:

          (i)  the replacement of the goods or the supply of equivalent goods;

          (ii) the repair of the goods;

          (iii) the payment of the cost of replacing the goods or of acquiring
               equivalent goods; or

          (iv) the payment of the cost of having the goods repaired; and

     (b)  if the breach relates to services:

          (i)  the supplying of the services again; or

          (ii) the payment of the cost of having the services supplied again.

                                                                             11.
<PAGE>
9.   DISPUTE RESOLUTION

9.1  DISPUTE RESOLUTION

     If a dispute arises out of or in relation to this document (including any
     dispute as to breach or termination of this document or as to any claim in
     tort, in equity or pursuant to any statute) (a DISPUTE), a party to this
     document may not commence any court or arbitration proceedings relating to
     the Dispute unless it has complied with this clause 9, except where the
     party seeks urgent interlocutory relief.

9.2  DISPUTE NOTICE

     A party claiming that a Dispute has arisen under or in relation to this
     document must give written notice to the other party specifying the nature
     of the Dispute (a DISPUTE NOTICE).

9.3  NEGOTIATION

     Upon receipt by a party of a Dispute Notice, Novogen and Glycotex must
     procure that their Managing Directors and President respectively meet to
     endeavour to resolve the Dispute expeditiously by negotiation.

9.4  RESOLUTION OF DISPUTES

     If the parties have not resolved the Dispute under clause 9.3 within 14
     days of receipt of the Dispute Notice, the parties must endeavour to
     resolve the Dispute expeditiously using informal dispute resolution
     techniques such as mediation, expert evaluation or determination or similar
     techniques agreed by the parties.

9.5  MEDIATION

     If the parties do not agree within 28 days of receipt of a Dispute Notice
     (or such further period as the parties agree in writing) as to:

     (a)  the dispute resolution technique and procedures to be adopted;

     (b)  the timetable for all steps in those procedures; and

     (c)  the selection and compensation of the independent person required for
          such technique,

     the parties must mediate the Dispute in accordance with the Mediation Rules
     of the Law Society of New South Wales, and the President of the Law Society
     of New South Wales (or the President's nominee) will select the mediator
     and determine the mediator's remuneration.

10.  TERM AND TERMINATION

10.1 TERM

     The rights and obligations of the parties under this document begin on the
     Commencement Date and end on the earlier of:

                                                                             12.
<PAGE>
     (a)  the date of termination in accordance with this clause 10; and

     (b)  the twelfth anniversary of the Commencement Date,

     or such later date as the parties agree in writing.

10.2 TERMINATION BY GLYCOTEX

     Glycotex may terminate this document at any time:

     (a)  on three month's written notice to Novogen;

     (b)  immediately if Novogen defaults in the performance of any of its
          obligations under this document which in Glycotex's reasonable opinion
          is capable of remedy and fails to remedy that default within 21 days
          of receiving written notice from Glycotex specifying the default and
          requiring the default to be remedied;

     (c)  on 21 days written notice if Novogen defaults in the performance of
          any of its material obligations under this document which in
          Glycotex's reasonable opinion is not capable of remedy; and

     (d)  immediately by notice in writing if:

          (i)  Novogen is involved in an Insolvency Event; or

          (ii) Novogen ceases for any reason to be able lawfully to carry out
               all the transactions which this document contemplates may be
               carried out by Novogen.

10.3 TERMINATION BY NOVOGEN

     Novogen may terminate this document at any time:

     (a)  immediately if Glycotex defaults in the performance of any of its
          obligations under this document which in Novogen's reasonable opinion
          is capable of remedy and fails to remedy that default within 21 days
          of receiving written notice from Novogen specifying the default and
          requiring the default to be remedied;

     (b)  on 21 days written notice if Glycotex defaults in the performance of
          any of its material obligations under this document which in Novogen's
          reasonable opinion is not capable of remedy; and

     (c)  immediately by notice in writing if:

          (i)  there is a Change in Control of Glycotex without Novogen's
               written consent;

          (ii) Glycotex is involved in an Insolvency Event; or

          (iii) Glycotex ceases for any reason to be able lawfully to carry out
               all the transactions which this document contemplates may be
               carried out by Glycotex.

                                                                             13.
<PAGE>
10.4 CONSEQUENCES OF TERMINATION

     Upon expiry or termination of this document for any each party must
     immediately return to the other party or destroy at its direction:

     (a)  all Confidential Information of the other party; and

     (b)  all materials, documents and other records containing, referring or
          relating to any Confidential Information of the other party,

     in its possession, custody or power.

10.5 SURVIVAL AND ACCRUED RIGHTS

     Upon termination under this clause 10, this document is at an end as to its
     future operation, except for:

     (a)  the enforcement of any right or claim which arises on or has arisen
          before termination; and

     (b)  the obligations of the parties under clauses 1, 7, 8.3, 9, 12 and 14
          (except clause 14.3) and this clause 10, which survive termination.

11.  FORCE MAJEURE

11.1 NOTICE AND SUSPENSION OF OBLIGATIONS

     If a party to this document is affected, or likely to be affected, by a
     Force Majeure Event:

     (a)  that party must immediately give the other prompt notice of that fact
          including:

          (i)  full particulars of the Force Majeure Event;

          (ii) an estimate of its likely duration;

          (iii) the obligations affected by it and the extent of its effect on
               those obligations; and

          (iv) the steps taken to rectify it; and

     (b)  the obligations under this document of the party giving the notice are
          suspended to the extent to which they are affected by the Force
          Majeure Event as long as the Force Majeure Event continues.

11.2 EFFORT TO OVERCOME

     A party claiming a Force Majeure Event must use its best endeavours to
     remove, overcome or minimise the effects of that Force Majeure Event as
     quickly as possible. However, this does not require a party to settle any
     industrial dispute in any way it does not want to.

                                                                             14.
<PAGE>
11.3 TERMINATION

     If a Force Majeure Event occurs for more than 30 days, either party may
     terminate this document by giving at least 21 days notice to the other
     party.

12.  NOTICES

     (a)  A notice, consent or other communication under this document is only
          effective if it is in writing, signed and either left at the
          addressee's address or sent to the addressee by mail or fax. If it is
          sent by mail, it is taken to have been received 3 working days after
          it is posted. If it is sent by fax, it is taken to have been received
          when the addressee actually receives it in full and in legible form.

     (b)  A person's address and fax number are those set out below, or as the
          person notifies the sender:

          NOVOGEN
          Address:      140 Wicks Road, North Ryde, NSW 2113 AUSTRALIA
          Fax number:   Int + 612 9878 0055
          Attention:    Managing Director

          GLYCOTEX
          Address:      140 Wicks Road, North Ryde, NSW 2113 AUSTRALIA
          Fax number:   Int + 612 9878 0055
          Attention:    President

13.  AMENDMENT AND ASSIGNMENT

13.1 AMENDMENT

     This document can only be amended, supplemented, replaced or novated by
     another document signed by the parties.

13.2 ASSIGNMENT

     A party may only dispose of, declare a trust over or otherwise create an
     interest in its rights under this document with the consent of each other
     party.

14.  GENERAL

14.1 GOVERNING LAW

     (a)  This document is governed by the law in force in New South Wales,
          Australia.

     (b)  Each party submits to the non-exclusive jurisdiction of the courts
          exercising jurisdiction in New South Wales, and any court that may
          hear appeals from any of those courts, for any proceedings in
          connection with this document, and waives any right it might have to
          claim that those courts are an inconvenient forum.

                                                                             15.
<PAGE>
14.2 LIABILITY FOR EXPENSES

     Each party must pay its own expenses incurred in negotiating, executing,
     stamping and registering this document.

14.3 GIVING EFFECT TO THIS DOCUMENT

     Each party must do anything (including execute any document), and must
     ensure that its employees and agents do anything (including execute any
     document), that the other party may reasonably require to give full effect
     to this document.

14.4 WAIVER OF RIGHTS

     A right may only be waived in writing, signed by the party giving the
     waiver, and:

     (a)  no other conduct of a party (including a failure to exercise, or delay
          in exercising, the right) operates as a waiver of the right or
          otherwise prevents the exercise of the right;

     (b)  a waiver of a right on one or more occasions does not operate as a
          waiver of that right if it arises again; and

     (c)  the exercise of a right does not prevent any further exercise of that
          right or of any other right.

14.5 OPERATION OF THIS DOCUMENT

     (a)  This document contains the entire agreement between the parties about
          its subject matter. Any previous understanding, agreement,
          representation or warranty relating to that subject matter is replaced
          by this document and has no further effect.

     (b)  Any right that a person may have under this document is in addition
          to, and does not replace or limit, any other right that the person may
          have.

     (c)  Any provision of this document which is unenforceable or partly
          unenforceable is, where possible, to be severed to the extent
          necessary to make this document enforceable, unless this would
          materially change the intended effect of this document.

14.6 OPERATION OF INDEMNITIES

     (a)  Each indemnity in this document survives the expiry or termination of
          this document.

     (b)  A party may recover a payment under an indemnity in this document
          before it makes the payment in respect of which the indemnity is
          given.

                                                                             16.
<PAGE>
14.7 CONSENTS

     Where this document contemplates that either party may agree or consent to
     something (however it is described), that party may:

     (a)  agree or consent, or not agree or consent, in its absolute discretion;
          and

     (b)  agree or consent subject to conditions,

     unless this document expressly contemplates otherwise.

14.8 EXCLUSION OF CONTRARY LEGISLATION

     Any legislation that adversely affects an obligation of a party, or the
     exercise by a party of a right or remedy, under or relating to this
     document is excluded to the full extent permitted by law.

14.9 COUNTERPARTS

     This document may be executed in counterparts.

                                                                             17.
<PAGE>
                                   SCHEDULE 1

                        CALCULATION OF FEES FOR SERVICES

The fees payable by Glycotex to Novogen for Services provided to Glycotex shall
be determined as follows:

1.   Within 14 days of the beginning of each financial year during the Term,
     Novogen shall prepare and provide to Glycotex, a budget estimate for the
     following financial year having regard to:

     (a)  the time spent by the employees and consultants of Novogen in the
          previous financial year in the provision of Services to Glycotex under
          this document; and

     (b)  any considerations of which it is aware which are likely to influence
          the time spent by the employees and consultants of Novogen in the
          following financial year in the provision of Services to Glycotex
          under this document.

2.   Each budget estimate prepared under paragraph 1 shall contain:

     (a)  a list of all employees and consultants who Novogen expects will
          provide Services to Glycotex during the financial year, together with
          their positions, and the salaries, consultancy fees or other
          remuneration payable by Novogen to those employees and consultants for
          that financial year;

     (b)  the allocated on-costs attributable to each person listed in paragraph
          (a), including fringe benefits tax, payroll tax, workers compensation
          insurance, superannuation charges and holiday and sick pay;

     (c)  the percentage of time Novogen expects each person listed in paragraph
          (a) to spend on the provision of Services to Glycotex under this
          document for the following financial year;

     (d)  the sum of the percentages for each person in paragraph (c) multiplied
          by the costs and charges for that person in paragraphs (a) and (b);

     (e)  a premises rental charge based on the floor space within Novogen's
          premises attributable to each person listed in paragraph (a);

     (f)  a general asset usage charge calculated on the basis of depreciation,
          amortisation and repairs and maintenance of Novogen's general assets
          used by each person listed in paragraph (a);

     (g)  a general overheads charge based on all other general outgoings in the
          operation of Novogen's business attributable to each person listed in
          paragraph (a);

                                                                             18.
<PAGE>
     (h)  a direct asset usage charge in relation to non-production assets
          directly attributable to Glycotex's business, calculated on the basis
          of depreciation, amortisation and repairs and maintenance of those
          assets; and

     (i)  a calculation of the budget estimate of fees payable by Glycotex for
          Services in the following financial year, being the sum of:

          (i)  the figure in paragraph (d);

          (ii) the figures in paragraphs (e), (f), (g) and (h); and

          (iii) an additional 10% of those figures.

3.   Within 14 days of receipt of a budget estimate under paragraph 1, Glycotex
     shall either accept the budget estimate provided by Novogen under paragraph
     1 or respond to Novogen with a revised budget estimate having regard to the
     assumptions and calculations in the estimate provided by Novogen.

4.   Within 7 days of receipt by Novogen of a revised budget estimate under
     paragraph 3, the parties shall negotiate in good faith to reach agreement
     on a budget estimate.

5.   The budget estimate accepted under paragraph 3 or agreed under paragraph 4
     shall become the agreed budget for the following financial year and shall
     be attached to this document as Annexure A.

6.   The fees payable by Glycotex to Novogen per month in consideration of the
     performance of the Services shall be one twelfth of the budget set out in
     Annexure A.

                                                                             19.
<PAGE>
EXECUTED as an agreement.

EXECUTED by NOVOGEN LIMITED:

/s/ Christopher Naughton                /s/ Ron Lea Erratt
-------------------------------------   ----------------------------------------
Signature of director                   Signature of director/secretary

CHRISTOPHER NAUGHTON                    RON LEA ERRATT
-------------------------------------   ----------------------------------------
Name                                    Name

EXECUTED by GLYCOTEX, INC.:

/s/ David Seaton                        /s/ David Seaton
-------------------------------------   ----------------------------------------
Signature of director                   Signature of director/secretary

DAVID SEATON                            DAVID SEATON
-------------------------------------   ----------------------------------------
Name                                    Name

                                                                             20.
<PAGE>
                                   ANNEXURE A

                                  AGREED BUDGET

                                                                             21.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00090-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00090-of-00352.parquet"}]]